Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-05-16
2004-11-16
Dentz, Bernard (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06818771
ABSTRACT:
The present invention relates to a process for the production of a naphthyridine carboxylic acid derivative having antibacterial activity.
EP 688772 discloses novel naphthyridine carboxylic acid derivatives, including anhydrous (R,S)-7-(3-aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid of formula I, having antibacterial activity.
WO 98/42705 (published after the priority date of the present application) discloses (R,S)-7-(3-aminomethyl-4-syn-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof including the sesquihydrate (the “methanesulfonate sesquihydrate”). WO 98/42705 discloses a process for the production of the methanesulfonate sesquihydrate comprising reaction of the corresponding free base with methanesulfonic acid in dichloromethane/ethanol followed by recrystallisation of the resulting crude salt anhydrate from either water:acetone (10:7 v/v), or water:ethanol (1:2 v/v). The overall yield for this two step process is 70-80%. An alternative process for the production of the methanesulfonate sesquihydrate described in WO 98/42705 comprises exposing a solvate of the methanesulfonate (ethanol 0.11%) to high relative humidity (nitrogen>93% humidity).
The present invention relates to an improved process for the production of the methanesulfonate sesquihydrate which comprises direct salt and hydrate formation.
According to the invention there is provided a process for the production of 7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate sesquihydrate which comprises reacting 7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and methanesulfonic acid in a solvent comprising at least one water miscible cosolvent and water, and isolating the resulting solid product.
The 7-(3-aminomethyl-4-syn-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid (hereinafter referred to as “the free base”) used in the process of the invention may be prepared as described in EP 688772.
Water miscible cosolvents which may be used in the process of the invention include C
1-8
alcohols, acetonitrile and dimethylformamide. The water miscible cosolvent is preferably a C
1-4
alcohol or a mixture thereof, e.g. methanol, ethanol and propanol; the preferred C
1-4
alcohol is isopropanol.
In addition to at least one water miscible cosolvent and water the solvent may contain other components, such as C
1-4
haloalkanes. However, the solvent preferably comprises essentially of a water miscible cosolvent and water.
Suitable ratios of water miscible cosolvent:water for use in the process of the invention include ratios in the range 10:1 to 1:2 v/v, preferred ratios are in the range 10:1 to 1:1 v/v, more preferably a ratio of water miscible cosolvent; water of 2:1 v/v is used.
Any suitable ratio of free base to solvent may be used, for example, a ratio of up to 1:100 w/v, particularly a ratio of about 1:9 w/v.
The process of the invention may suitably use from 0.7 to >3 mole equivalents of methanesulfonic acid, preferably 0.7 to 1.5 equivalents, more preferably 0.9 to 1.5 equivalents, especially about 1.0 equivalent of methanesulfonic acid (based on the free base).
The mixture of the free base and methanesulfonic acid may be warmed in the solvent to aid dissolution. On cooling the methanesulfonate sesquihydrate will crystallise out of solution. To aid crystallisation the solution may be seeded with a small quantity of solid methanesulfonate sesquihydrate. In order to obtain polymorphically pure methanesulfonate sesquihydrate it is preferable that seeding of the solution is completed before crystallisation begins. Seeding of the crystallisation solution is preferably performed at a temperature ≧25° C., for example at a temperature of about 30° C.
The process of the invention may be used to produce racemic methanesulfonate sesquihydrate or may be used for the production of enantiomerically enriched or enantiomerically pure methanesulfonate sesquihydrate, using racemic or enantiomerically enriched or enantiomerically pure free base. Enantiomerically enriched or enantiomerically pure free base may be prepared by resolution of the racemic free base, e.g. by chiral HPLC.
The process according to the invention has the advantage that direct salt formation eliminates one step in the synthesis and gives a high yield of high purity methanesulfonate sesquihydrate. In turn these advantages result in improved throughput and savings in labour and materials costs during manufacture.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
The invention is illustrated by the following example. However, it should be understood that the example is intended to illustrate but not in any manner limit the scope of the invention.
REFERENCES:
patent: 5633262 (1997-05-01), Hong et al.
patent: 5776944 (1998-07-01), Hong et al.
patent: 5869670 (1999-02-01), Hong et al.
patent: 5962468 (1999-10-01), Hong et al.
patent: 6307059 (2001-10-01), Chang et al.
patent: 2002/0032216 (2002-03-01), Kim et al.
patent: 0 058 614 (1982-08-01), None
patent: 0 688 772 (1995-12-01), None
patent: 0 805 156 (1997-11-01), None
patent: 03 056479 (1991-03-01), None
patent: WO 91 02526 (1991-03-01), None
patent: WO 96 39406 (1996-12-01), None
patent: WO 97 07098 (1997-03-01), None
patent: WO 97 36874 (1997-10-01), None
patent: WO 98 42705 (1998-10-01), None
patent: WO 99 61420 (1999-12-01), None
Patent Abstracts of Japan, vol. 015, No. 202 (C-0834), May 23, 1991 (JP03056479A, Mar. 12, 1991).
G. Cormican, “Comparative Antimicrobial and Spectrum Activity of LB20304a, a New Fluoronated Naphthyridone Compound”,Abstracts of the 36th ICAAC, 109 Abst F53 (1996).
J-H. Kwak, “Antimicrobial Activities of LB20304a, a New Quinolone Antibiotic”,The Journal of Applied Pharmacology(4) pp. 378-384 (1996).
M-K, Seo, “Pharmacokinetics of LB20304, a New Fluoroquinolone, in Rats and Dogs”,Arch. Pharm. Res.vol. 19, No. 5, pp. 359-367 (1996).
C. Yong Hong, et al., “Novel Fluoroquinolone Antibacterial Agents Containing Oxime-Substituted (Aminomethyl) pyrrolidines: Synthesis and Antibacterial Activity of 7-(4-Aminomethyl)-3-(methoxyimino) pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro [1,8] naphthyridine-3-carboxylic Acid (LB20304)”,J. Med. Chem,.40 (22) pp. 3584-3593 (1997).
M-K. Seo et al., “High Performance Liquid Chromatographic Assay of a New Fluoroquinone, LB20304, in the Plasma of Rats and Dogs”,Arch. Pharm. Res.vol. 19, No. 6, pp .554-558 (1996).
M-J. Ahn, et al., “InVivo Efficacy of LB20304a, against Experimental Respiratory Tract Infection in Mice”,Yakhak Hoejivol. 40, No. 4, pp. 438-441 (1996).
M-J. Ahn, et al., “Effect of a New Fluoroquinolone LB20304a on Microflora of Caecum in Mice”,Yakhak Hoejivol. 40, No. 3, pp. 343-346 (1996).
M-J. Ahn, et al. “Post-Antibiotic Effect of LB20304, A New Quinolone Antibiotic”,Yakhak Hoejivol. 40, No. 3, pp. 347-350 (1996).
F. Marco, et al., Äntimicrobial Activity of LB20304, a Fluoronaphthyridone, Tested Against Anaerobic Bacteria,J. Antimicrobial Chemothervol. 40, No. 4, pp. 605-607 (1997).
Kelly et al., “Antipneumococcal Activity of SB 265805 (A New Broad Spectrum Quinolone) Compared with Nine Compounds by MIC,” 38th ICAAC, San Diego CA, Abst F-87, p. 254 (1998).
U.S. application Ser. No. 09/381,491, filed Dec. 8, 1999, Salt of Naphthyridine Carboxylic Acid Derivative, Kim et al.
U.S. application Ser. No. 09/623,214, filed Aug. 30, 2000, Process for Preparing a Protected 4-Aminomethyl-Pyrrolidin-3-One, Chang et al.
Hayes Jerome Francis
Walsgrove Timothy Charles
Wells Andrew Stephen
Dentz Bernard
Finnegan, Herderson, Farabrow, Garrett & Dunner, L.L.P.
LG Life Sciences Limited
LandOfFree
Process for the production of a naphthyridine carboxylic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for the production of a naphthyridine carboxylic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the production of a naphthyridine carboxylic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3332066